Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:
Therapeutic Areas/Disease States:
Pediatric Cancers, including fibrosarcoma, glioma, nephroma, thyroid cancer, etc. (nmCRPC)
Intended Audience: Oncologists, Surgeons, Pediatricians, Endocrinologists, Pathologists, Community HCPs, Patients/Caregivers
Areas of interest based on referenced literature:
- Treatment and management of pediatric cancers, including fibrosarcoma, glioma, nephroma, thyroid cancer, etc.
- Role of NTRK gene fusion and impact of TRK gene fusion/TRK testing in treatment algorithms
- Treatment and management of TRK fusion cancers in children
- Understanding of efficacy and safety profiles of approved TRK inhibitors
- Multi-disciplinary approach to precision medicine
Proposal Requirements:
All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:
- Needs assessment
- Educational design and rationale for selection (where applicable)
- Learning objectives
- Proposed faculty
- Participant recruitment plan (where applicable)
- Outcomes strategy/plan (required on a quarterly basis)
- Detailed budget
Provider Justification:
- Copy of most recent accreditation letter and status
- Sample of other program(s) in similar therapeutic areas
Process
Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.
Acceptance of a Bayer educational grant indicates that you will:
- Reconcile grant funding within 60 days of completion of the educational program
- Permit a BHC Medical Affairs representative to audit live programs
- Share activity data and outcomes metrics within 30 days of their availability
References
Management and treatment of pediatric cancers
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Adolescent and Young Adult (AYA). Version 1.2020 – July 11, 2019 (Link)
Appropriate sequencing and combinations of agents in mCRPC
- Hong DS, Bauer TM, Lee JJ et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 Feb 1;30(2):325-331. (Link)
- Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family protein in cancer. Pharmacol Ther 2017 (173), 58-66. (Link)
- Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (Link)
- Cocco, E et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. (Link)
- Albert, CM et al. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. J Clin Oncol. 2019 Feb 20;37(6):513-524. (Link)
- Hyman, DM et al. Durability of response with larotrectinib in adult and paediatric patients with TRK fusion cancer. Annals of Oncology 30 (5), October 2019 (Link)
- Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstr 6602) (Link)
- Cocco, E et al. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Res. 2019 Mar 15;79(6):1047-1053. (Link)
- Ricciuti, B et al. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019 Apr 30;12:3171-3179 (Link)
- Solomon, JP et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2019 Aug 2. (Epub ahead of print) (Link)
- Wong, D et al. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer. Pathol Oncol Res. 2019 Jun 29. (Epub ahead of print) (Link)
- van Tilburg, CM et al. Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients. Journal of Clinical Oncology 37, 2019 (suppl; abstr 10010) (Link)
- Perreault, S. et al. Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumors. ACO 2021 Presentation
- Albert, CM. et al. Larotrectinib in pediatric patients with TRK fusion sarcomas: Updated efficacy and safety. CTOS 2021 Presentation
- Mascarenhas, L. et al. Larotrectinib demonstrates durable efficacy and safety in an expanded dataset of paediatric patients with TRK fusion cancer. SIOP 2020 Presentation
- ascarenhas L et al., Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset. Journal of Clinical Oncology Volume 40, Number 16_suppl. 2022 (Link)
- Laetsch TW et al., Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A. Journal of Clinical Oncology. Volume 41, Number 16_suppl 2023 (Link)
- Dizdarevic S. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1102-1110 (Link)
- Federman et al,. Long-term follow-up of the efficacy and safety of larotrectinib in pediatric patients with TRK fusion cancer. Abstract SIOP 2023 (Link)